How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?

Topics: Medical Oncology • Bone Marrow Transplant • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question

What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?

Answer from: Medical Oncologist at Academic Institution

Biochemical relapse (i.e. increase in M-spike or light chains meeting criteria for progression on two occasions without clinical progression) is an indication for starting treatment in my opinion. I have seen some recommend increasing the dose of lenalidomide to 25 mg in the hopes this will bring di...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Agree on all fronts with @Ben Derman's excellent r...

Medical Oncologist at Northwest Georgia Oncology Centers
Our patients typically receive Dara RVD per GRIFFI...

Related Questions